Fabian Franke (Postdoc, 2020-2023) worked in the translational team to develop interleukin-based biopharmaceutical lead candidates.

Nicolas Blömeke (PhD & Postdoc, 2016-2022) discovered that Calnexin can recognize non-glycosylated clients via its transmembrane domain.

Babsi Strasinsky (team assistant, 2021-2022) was responsible for setting up our lab administration and keeping the lab running.

Karen Hildenbrand (PhD, 2017-2022) found out that human interleukin 35 looks different than we thought, and thus discovered two new human cytokines.

Korbinian Liebl (Postdoc, 2021-2022) supported and spearheaded several interleukin engineering projects with his computational expertise.

Amelie Eichenseer (Lab technician, 2020-2022) was part of our translational team and developed assays key for our interleukin-based biopharmaceuticals.

Joao Coelho (PhD, 2016-2021) could show that multiple chaperones work on faulty membrane proteins in a concerted manner, and discovered that the human signal peptidase functions as a quality control protein.

Yonatan Mideksa (PhD, 2016-2021) spearheaded genetic code expansion in our lab and comprehensively characterized interleukin chaperones in the endoplasmic reticulum.

Susanne Meier (PhD, 2015-2019) was the first to describe how interleukin 12 and interleukin 23 assembly control functions on a molecular level.

Stephanie Müller (PhD, 2015-2019) revealed how cells make interleukin 27, and used these insights to engineer novel interleukin-based drug candidates.

Beat Thippayajan (Lab technician, 2016-2017) kept our lab running and worked on several interleukin projects in the lab